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j ourna l homepage: www.e lsev ie r .com/ locate /atgEmerging Translational Research Methods: A SamplingIt’s hardly news that new genomic technologies are more precisely
characterizingmicrobes, plants, humans for the purpose of understand-
ing disease mechanism, identifying causes of pathologies, improving
clinical care, prevention and ultimately public health, in its broadest
sense. Innovations in identiﬁcation techniques, alongwith bioinformat-
ics tools are enabling faster and more accurate identiﬁcation of genetic/
genomic elements that play vital roles in the development of disease.
The articles in this issue present novel innovative technologies that
demonstrate improvements over conventional tools and thus represent
signiﬁcant steps forward inmore accurate identiﬁcation. The ﬁrst paper,
‘Identiﬁcation and Conformational Analysis of Putative microRNAs in
Maruca vitrate (Lepidoptera: Pyralidae’ describes the in silico identiﬁca-
tion of 13 putative micro RNAs in M. vitrate, which is an important crop
pest insect. Habeeb and Sureshan’s demonstrate that the sequence com-
position can inﬂuence the stem-loop hairpin structure of pre-miRNAs,
which can affect the location of binding enzymes. They suggest that
these identiﬁed miRNAs can be potentially useful in effective pest man-
agement. The second paper “Developmental neurotoxic effects of Mala-
thion on 3D neurosphere systems’ addresses two limitations in
translational CNS research, namely that available animal models do
not cover the whole spectrum of CNS development periods, including
but not limited to the fact that putative toxicants cannot be identiﬁed
and conﬁrmed with certainty. Mohamed et al, present a novel method
for predicting neurotoxic effects. UsingMalathion, an organophosphate
pesticide with suggested neurotoxic affects on nursing children, the au-
thors report a novel in-vitro system that recapitulates the changes oc-
curring during early brain development and thus can serve as an
improved model for predicting the development of neurotoxic effects.
They demonstrate the abstract developmental neurotoxicity (DNT) ef-
fects on of Malathion on 3D neurospheres system model and present a
detection method that overcomes the limitations of conventional tech-
niques used in 3D neurospheres. A considerable challenge in advancing
translational genomics is determining which of several alternative
methods is superior for a particular inquiry. The next two articles ad-
dress this issue as applied to identiﬁcation and diagnosis of neurological
pathology in epileptic and neuromuscular disorders. In ‘Comparison of
two next-generation sequencing kits for diagnosis of epileptic disorders
with a user friendly tool for displaying gene coverage, DeCovA’, Lesca
et al compare two commonly-used targeted capture techniques for
next generations sequencing libraries, two softwares for variant analysis
and the development of their novel tool DeCovA for displaying coverage
and depth data. Their study demonstrates that neither of the commonly
used Next Gene and Ion Reporter could identify all the known muta-
tions/CNVs. Their tool, DeCovA showed that detection failure was pri-
marily due to insufﬁcient coverage. DeCovA may be useful, therefore,http://dx.doi.org/10.1016/j.atg.2015.11.001
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targeted exome approach, MyoPanel2, designed to optimize clinical di-
agnosis of neuromuscular disorders. Analyzing 306 genes known to be
mutated inmyopathies and related disorders, MyoPanel2 demonstrates
a 98.8 target sequence coverage at 20x and 99.7% detection of 11,467
knowmutations responsible for neuromuscular disorders. Their results
suggest that targeted exome sequencing may be an efﬁcient clinical di-
agnosticmethod formost neuromuscular disorders. In ‘Highly sensitive,
non-invasive detection of colorectal cancer mutations using single mol-
ecule third generation sequencing’, Russo et al present a novel method
for a non-invasive and highly sensitive assay for population screening
for colorectal cancer and early stage adenomas that lead to CRC. This is
the ﬁrst study that applies high read accuracy and depth of single mol-
ecule, real time, circular consensus sequencing (SMRT-CCS) to the de-
tection of mutations in stool DNA in order to provide a non-invasive,
sensitive and accurate test for colorectal cancer. In stool DNA isolated
from patients with adenocarcinoma, researchers detected mutations
at frequencies below 0.5% and with no false positives. The proposed
method suggests an important advancement in light of the fact that
none of the numerous non-invasive CRC screening methods attempted
over the past twenty years have been established. Finally, in ‘Application
of Smart Infrastructure Systems Approach to Precision Medicine’,
Govindaraju andAnnaswamy propose a novel systems approach to pre-
cisionmedicine which can accomplish the need to incorporate multiple
modalities of human variation data. The SIS is a broad trans-disciplinary
approach that represents an advance over current approaches in that it
manages complex networks on non-linear adaptive controls while also
takes into account antecedent and attendant aspects of health and dis-
ease. In other words, the SIS can integrate all features of complex varia-
tion amongst populations, families and individuals, combining different
factors such as genomics, tissues, exposure, migration data, while being
integrated, adaptive, reactive, predictive and optimized. The conceptual
basis and mathematical foundation of the SIS are laid out.
Together, these articles provide a window into some of the many
technological challenges to advancing translational research and diag-
nostic tools, while displaying successful new approaches overcome spe-
ciﬁc limitations in conventional techniques.Wewelcome your thoughts
as Letters to the Editor.
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